Introduction {#s1}
============

Preeclampsia is one of the most important complications dduring pregnancy with unknown etiology which is associated with hypertension and proteinuria with a prevalence of 5-8% of all pregnancies worldwide. There are many ideas concerning the etiology and pathogenesis of preeclampsia including endothelial dysfunction, inflammation and angiogenesis.^[@R1]^ Homocysteine (Hcy) is a toxic, non-proteinogenic, sulfur-containing, highly reactive amino acid, which is synthesized in the course of protein catabolism by the conversion of methionine to cysteine.^[@R2]^ Methylene tetrahydrofolate reductase (MTHFR) catalyzes the reduction of 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, which is the major circulating form of folate. The 5-methyltetrahydrofolate is a donor of methyl for the vitamin B12-dependent remethylation of Hcy to methionine. It has been shown that the most important reason for hyperhomocysteinemia and/or lack of methionine is the polymorphism of MTHFR gene.^[@R3]^ MTHFR 677C\>T mutation has been recognized with 40% reduction in its activity of the CT (heterozygote) and with very low activity (about 70% reduction) of the TT (homozygote) form.^[@R4]^ Recent evidence suggested a relationship between high levels of blood circulating Hcy in women with gestational hypertension and preeclampsia.^[@R5]^ Increased circulating Hcy as a predisposing risk factor for peripheral vascular diseases, could be one of the independent risk factors for preeclampsia.^[@R6]^

Lipoprotein(a) \[Lp(a)\] as a plasma lipoprotein consists of low-density lipoprotein cholesterol (LDL-C) particle and the glycoprotein apolipoprotein(a) covalently bounded to apolipoprotein B100 of the LDL-C particle.^[@R7]^ Apolipoprotein (a) has been reported to have structural similarities to plasminogen and to inhibit plasminogen activity in-vitro. In consequence, a reduction in the activity of plasminogen leads to a reduction in the clot lysis. Pregnancy is a condition of hyperlipidemia and hypofibrinolysis which may be essential for normal placental development.^[@R8]^ Preeclampsia demonstrates an exaggerated inhibition of the fibrinolysis which, in-part, results from an increase in plasma plasminogen inhibition. Serum Lp(a) level is elevated in the preeclampsia which is associated with severity of the disease.^[@R9]^

In vitro studies have demonstrated that Hcy enhances the binding of Lp(a) to fibrin by altering fibrinolysis.^[@R10]-[@R14]^ In the preeclampsia, a more exacerbation of the hypercoagulable condition is noticed, compared to the normal pregnancy.^[@R15]^ Folic acid (FA) supplementation can increase serum folate concentrations and decline Hcy concentrations.^[@R16]^ Hyperhomocysteinemia can be considered as one of the chronic oxidative stress factors which enhances the vascular inflammation that results in increase in the concentrations of fibrinogen and Lp(a). Taking into account the possible interactions between Hcy, fibrinogen, and Lp(a), vitamin B groups may also affect the status of fibrinogen and Lp(a).^[@R17]^ Limited studies have investigated the association between genetic polymorphisms in MTHFR gene and the effects of FA supplementation on serum Hcy levels. This study aimed to assess if MTHFR genotypes (677C→T) can influence plasma Hcy and Lp(a) concentrations in response to high dose of FA supplementation.

Ma­terials and methods {#s2}
======================

Materials {#s2-1}
---------

Serum concentrations of Hcy were measured by commercially Enzyme-Linked Immunosorbent Assay (ELISA) kits (AXIS Co). Lp(a) was obtained from Pars Azmoon Co (Tehran, Iran). Serum urea, uric acid, lactic dehydrogenase, creatinine, urine protein and urine creatinine were determined using commercial reagents with an automated chemical analyzer (Abbott Analyzer, USA). Genomic DNAs were extracted from whole blood according to the manufacturer's protocol in Kit (RON'S Blood and Cell DNA Mini Kit).

Subjects {#s2-2}
--------

This study was set up as a clinical trial including one hundred thirty nulliparous women who visited the AL-Zahra Hospital, Tabriz Iran, from September 2013 to November 2014 for prenatal tests and planning to be pregnant. All the participants had signed written informed consent. Among the participants only healthy women aged between 20-30 years old without any history of medical problems including heart disease, chronic hypertension, diabetes mellitus, chronic renal disease, collagen tissue disease, preterm delivery, abortion, and liver disease were included in the study. Sever preeclampsia was defined as blood pressure (BP) ≥160/110 mm Hg, proteinuria≥2.0 g/24 h, serum creatinine\>1.2 mg/dL unless known to be previously elevated, platelets \<100.000/mm^3^ , microangiopathic hemolysis (increased LDH), persistent headache or other cerebral or visual disturbance.

Sample collection and analysis {#s2-3}
------------------------------

Baseline venous blood samples were collected after overnight fasting at 3-month intervals before conception. After collecting baseline samples, participants received FA (5 mg/day) for 36 weeks after initiation of pregnancy. The participants were contacted every week and asked during each visit to declare whether they took FA supplementation or not. Second sampling was done 36 weeks after pregnancy. Mothers who had abortion and taking medications other than calcium and ferrous sulfate and did not complete the follow up visit were excluded from the study. Serum samples were isolated from whole blood and after centrifugation (at 3000 rpm) for 20 min stored in a freezer at -70°C for Lp(a) and Hcy analysis.

Genotyping of the MTHFR gene variant {#s2-4}
------------------------------------

The quantity and quality of the extracted DNA were checked using UV absorption measurement, Eopoch. BioTek (Winooski, VT, USA). The A260/A280 ratio of DNA samples was in high quality between 1.7--2.0A. The PCR solution contained 110 ng genomic DNA, 1x PCR buffer, 0.3 mM of each primer, 10 nmol of each dNTP, 1.5 mM MgCl~2~ and 1 U Taq polymerase in a final volume of 25 µL. Polymorphisms of MTHFR (677) was evaluated by using ARMS-PCR method. In ARMS-PCR method, amplification of DNA was performed using three primers for each polymorphism, one forward primer (TGCTGTTGGAAGGTGCAAGAT) and two reverse primers (for mutant primer; GCGTGATGATGAAATCGA, for normal primer; GCGTGATGATGAAATCGG). Primer Blast at NCBI site and primer 3Plus software for primer design were applied. PCR products were separated on 1% agarose gel. To determine DNA fragments, Thermo Scientific Gene Ruler 50 bp DNA Ladder was used ([Fig. 1](#F1){ref-type="fig"}).
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Statistical analysis {#s2-5}
--------------------

Statistical analysis was performed by SPSS software version 18.0 (SPSS Ins, Chicago, IL, USA). Results were expressed as median (minimum-maximum), or mean±SD. We checked the distribution of variables by Kolmogorov-- Smirnov test, Skewness and also Kurtosis of data before starting statistical analysis. The results showed that our data is not normally distributed so we used Kruskal-Wallis test to compare three groups of cases (CC, TT and CT genotypes) on one variable. The Wilcoxon and Kruskal-Wallis tests were also applied to assess the significance of differences between the baseline and delivery time. Correlation was evaluated by Pearson's test and the statistical significance was set at p \< 0.05.

Results {#s3}
=======

One hundred and thirty pregnant women were initially recruited. Forty women failed to complete the study period (10 cases had abortion, 2 cases had multiple pregnancies, 13 cases quit taking their supplements and 15 cases did not come to the second round of sampling 36 weeks after pregnancy) and all the analysis were performed on a total of 90 cases. The demographic characteristics and biochemical data of the population under studying were summarized in [Table 1](#T1){ref-type="table"}. There was no clinically apparent case of hypertension. The mean changes of Hcy and Lp(a) at the baseline and at the 36th week of pregnancy were shown in [Table 2](#T2){ref-type="table"}. Although the mean serum levels of Hcy at the 36th week of pregnancy were significantly lower in the women receiving FA supplementation (p = 0.001), no statistically significant changes were observed in Lp(a) levels (p= 0.17). The results from laboratory analysis of Hcy and Lp(a) levels at the baseline and at the 36th week of pregnancy after treatment with FA supplementation, stratified by MTHFR C677T were shown in [Table 3](#T3){ref-type="table"}. The prevalence of MTHFR C677T polymorphisms 677 CC, 677 CT, and 677 TT were 53.3%, 26.7%, and 20.0%, respectively. Although there was no significant association between serum Lp(a) levels and MTHFR C677T genotype (p\>0.1, In all three genotypes), Hcy levels decreased markedly in all three genotypes (CC: P\<0.001, CT: p\<0.001, TT: p\<0.02).

###### Demographic characteristics and biochemical data of pregnant women

  --------------------------- -----------------------------
  **Variable**                **Pregnant woman (n= 90)**\
                              **(Mean ± SD)**

  Age (years)                 27.07 ± 4.86

  LDH (IU/L)                  359.56 ± 82.01

  Uric acid (mg/dL)           3.89 ± 1.02

  Urea (mg/dL)                27.31 ± 1.18

  Serum creatinine (mg/dL)    0.80 ± 0.11

  Urine creatinine (g/24 h)   0.73 ± 0.09

  Platelet count (µL)         229.11 ± 49.21

  BMI (kg/m^2^)               25.37 ± 3.63

  Systolic BP(mm Hg)          119.78 ± 9.17

  Diastolic BP(mm Hg)         80.00 ± 3.69

  Urine protein (mg/24 h)     148.42 ± 79.04
  --------------------------- -----------------------------

LDH: lactate dehydrogenase; BMI: Body Mass Index.

###### The mean changes of homocysteine and lipoprotein (a) concentrations at baseline and at the 36th week of pregnancy after treatment with folic acid supplementation

  ---------------- -------------------- ------------------- -----------------
  **Parameters**   **Baseline**\        **36thweek**\       **p-value** ^a^
                   **n=90**             **n=90**            

  Hcy (µmol/L)     11.40 (4.40-28.70)   9.70 (1.60-20.80)   0.001\*

  Lp(a) (mg/ dL)   3.60 (0.47-33.00)    4.30 (0.37-31.00)   0.17
  ---------------- -------------------- ------------------- -----------------

Hcy: Homocysteine; Lp (a): Lipoprotein (a); Data are expressed as median (minimum--maximum).

^a^Before treatment vs. after treatment with folic acid supplementation. (Values were obtained by a Wilcoxon test.)

\*Significant difference.

###### The mean changes of homocysteine and lipoprotein (a) concentrations at baseline and at the 36th week of pregnancy after treatment with folic acid supplementation stratified by MTHFR C677T genotype

  -------------------------------------------------- -------------------- -------------------- ------------------- -------------
  **Parameters**                                     **CC**\              **CT**\              **TT**\             **p-value**
                                                     **n =48**\           **n =24**\           **n =18**\          
                                                     **% =53.3**          **% =26.7**          **% =20.0**         

  **Hcy (µmol/L) \[median (minimum--maximum)\]**                                                                   

  Baseline                                           12.40 (4.40-28.70)   10.45 (6.80-21.00)   9.95 (6.00-20.60)   0.06^a^

  36th week                                          11.30 (1.60-20.80)   7.75 (5.80-17.70)    9.15 (3.50-18.70)   0.08^b^

  p-value                                            0.001^c^             0.001^c^             0.02^c^             

  **Lp (a) (mg/dL) \[median (minimum--maximum)\]**                                                                 

  Baseline                                           4.35 (0.65-33.00)    3.60 (.47-17.80)     3.20 (1.30-10.6)    0.58^a^

  36th week                                          4.40 (1.00-31.00)    4.40 (2.20-16.60)    3.60 (0.37-26.90)   0.55^b^

  p-value                                            0.16^c^              0.44^c^              0.68^c^             
  -------------------------------------------------- -------------------- -------------------- ------------------- -------------

Hcy: Homocysteine; Lp(a): Lipoprotein (a)

^a^Comparison of Hcy and Lp(a) among different genotypes before treatment(Values were obtained by a Kruskal-Wallis test).

^b^ Comparison of Hcy and Lp(a) among different genotypes after treatment (Values were obtained by a Kruskal-Wallis test).

^c^Before treatment vs. after treatment with folic acid supplementation in each genotype (Values were obtained by a Wilcoxon test).

Discussion {#s4}
==========

The endothelial cell injury in preeclampsia has multifactorial causes. Typical pathological lesions in the placenta, affected by preeclampsia, are fibrin deposits, acute atherosclerosis and thrombosis. The resemblance between the lesions of preeclampsia and atherosclerosis has led to assumptions of a common pathophysiological pathway. Elevated plasma Lp(a) and Hcy concentrations were identified as risk factors for atherosclerotic cardiovascular diseases.^[@R11]^ In preeclampsia, an increased exposure to risk factor(s) such as abruption placenta, acute renal failure, cerebrovascular and cardiovascular complications, and maternal death have been reported.^[@R18],[@R19]^ Our data showed that supplementation of pregnant women with FA decreased the total plasma Hcy levels. Sayyah et al observed a protective role for FA in the group who continued FA in a dose of 5 mg/day through gestation. In that study the Hcy levels were lower than the group who received 0.5 mg/day and blood pressure was not increased to the eclampsia/preeclampsia borders.^[@R20]^ Papadopoulou et al showed that high doses of supplemental FA (\>5 mg/day) in early-to-mid gestation may prevent preterm birth, low birth weight, and small for gestational age neonates.^[@R21]^ In the present study, we found that the mean serum levels of Hcy at the 36th week of pregnancy after treatment with FA (5 mg/day) supplementation were significantly lower in comparison with baseline state. Our study confirmed McDowell et al results in that the high doses of FA (5 mg/day) significantly reduced the total Hcy levels.^[@R22]^ Although Adank et al demonstrated that weekly high-dose FA supplement (2,800 µg) was effective as a daily supplement in lowering Hcy concentrations in healthy women of childbearing age,^[@R23]^ Li et al^[@R24]^ suggested that daily consumption of 400 μg FA alone during early pregnancy cannot prevent the occurrence of gestational hypertension and preeclampsia. Our findings were not consistent with Fernandez et al results which observed basal Hcy levels were not affected by FA in a dose of 1 mg/day after three months supplementation.^[@R25]^ Often this supplementation does not protect against hyperhomocysteinemia, possibly because the usual daily doses of FA are too low.

It has been shown that, there is a 2-fold increase in Lp(a) during normal pregnancy, which may influence fibrinolysis.^[@R26]^ On the other hand, Parvin and Mori et al pointed out an association between elevated levels of Lp(a) and preeclampsia.^[@R27],[@R28]^ Satter and Baksu et al showed no statistically significant differences between normotensive pregnant, and preeclamptic women, with respect to plasma Lp(a) levels.^[@R26],[@R29]^ Harpel et al^[@R30]^ revealed that Hcy, even at a low concentration of 8 µmol/L, could modify the structure of Lp(a) by exposing lysine-binding domains in the apo(a) molecule. In consequence, the binding between Lp(a) and fibrin was significantly increased. Activation of coagulation in preeclampsia occurred at an early phase of the disease and antedated the clinical symptoms.^[@R15]^ Furthermore, it was demonstrated that the administration of vitamin B causes decline of Hcy, Lp(a) and fibrinogen.^[@R17]^ The result of our study showed that by administrating FA, Hcy levels were decreased in all three MTHFR genotypes but Lp(a) status were not statistically influenced. Also no significant correlation between serum Hcy and Lp(a) concentrations during the FA supplementation was detected.

The MTHFR polymorphism is associated with increased risk of cardiovascular disease, neural tube defects, occlusive arterial disease, cognitive decline and osteoporosis. Polymorphism of MTHFR C677T caused a decrease in enzyme activity, which may lead to an increase in the concentration of plasma Hcy and lower levels of serum folate, particularly in those with low folate intake.^[@R31]^ Xianhui et al demonstrated that MTHFR C677T polymorphism not only affects on Hcy concentrations at baseline and after FA treatment, but also can modify responses to various dosages of FA supplementation.^[@R32]^ They found that after four or eight weeks of treatment with high dose of FA, subjects with MTHFR 677 TT genotype had significantly greater decrease in Hcy levels compared to CC genotype. We found that the magnitude of the reduction in Hcy levels with FA administration was irrespective of MTHFR genotypes. In contrast, several authors^[@R33],[@R34]^ demonstrated that the effect of FA supplementation was most different in persons with the highest Hcy concentrations at baseline and in persons homozygous for the 677 C→T mutation of the MTHFR-gene. Williams et al showed that MTHFR genotype CC homozygote's (without the 677C→T polymorphism) with normal blood pressure had a larger reduction in Hcy concentrations in response to FA (5 mg) than did T allele carriers.^[@R35]^ The discrepancies can be explained by applied methods, study design, sample sizes and ethnicity of study populations. Similar to our results, several authors, demonstrated that the effect of FA supplementation may be unrelated to MTHFR genotype.^[@R36],[@R37]^

Additional large sample studies also are needed to further examine the relationship of FA treatment with Hcy and Lp(a) change and the possible effect of high dose of FA which was administrated throughout pregnancy on serum Hcy and Lp(a) levels in MTHFR (677C→T).

Conclusion {#s5}
==========

Based on our findings, the FA supplementation can decrease the serum levels of Hcy, while Lp(a) status was not statistically influenced. Further, the effect of FA supplementation may be unrelated to the MTHFR genotype in the pregnant women.
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Research Highlights {#s9}
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What is current knowledge?√ Elevated total homocysteine (Hcy) and lipoprotein (a) \[Lp(a)\] are risk factors for the endothelial dysfunction.What is new here?√ The FA supplementation can decrease the serum levels of Hcy in all three methylenetetrahydrofolate reductase polymorphisms (MTHFR), however the serum level of Lp(a) did not change in the pregnant women.
